Compare BioNano Genomics Inc (BNGO) vs PubMatic Inc (PUBM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs PubMatic Inc — how do they compare? BioNano Genomics Inc trades at $1.24 (market cap $13.66M), while PubMatic Inc trades at $17.52 (market cap $804.41M). The key difference: PubMatic Inc is far larger — about 58.9× BioNano Genomics Inc's market cap, and PubMatic Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | PUBM | |
|---|---|---|
Market Cap | $13.66M | $804.41M |
Sector | Health | Technology |
52-Week High | $4.92 | $17.78 |
52-Week Low | $1.06 | $6.28 |
Enterprise Value | $16.26M | $707.54M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
PUBM trades at $17.18, down 3.27% over 24 hours, with a bullish technical signal from moving averages but bearish oscillators. The company reported a Q2 2026 earnings beat with 11% revenue growth, driven by mobile app and CTV segments, though it remains unprofitable with a negative net income margin. Recent news highlights strategic hires and product launches like AgenticOS to capitalize on AI in advertising.
The outlook is mixed: strong revenue growth and analyst buy ratings support upside to the $20.83 consensus target, but profitability challenges and high valuation ratios pose risks. Investors should weigh the growth potential in high-margin segments against persistent losses and competitive pressures in the ad tech space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →
